Polypharmacy in hospice patients - current situation, threats associated with adverse effects and drug-drug interactions and therapeutical implications

被引:0
作者
Kotlinska-Lemieszek, Aleksandra [1 ,2 ]
Zaporowska-Stachowiak, Iwona [2 ,3 ]
机构
[1] Uniwersytet Medyczny im Karola Marcinkowskiego Po, Katedra Klinika Medycyny Paliatywnej, Poznan, Poland
[2] Szpital Kliniczny Przemienienia Panskiego Poznani, Oddzial Medycyny Paliatywnej, Poznan, Poland
[3] Uniwersytet Medyczny im Karola Marcinkowskiego Po, Katedra Zaklad Farmakol, Poznan, Poland
来源
MEDYCYNA PALIATYWNA-PALLIATIVE MEDICINE | 2013年 / 5卷 / 03期
关键词
polytherapy; palliative care; adverse effects; interactions;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Patients in palliative care take 0-20 drugs, with amean 5-7. These include drugs used for symptom control, the treatment of concomitant diseases, and in some cases anticancer agents. Drugs used most commonly include: opioids (ap. 80-85% patients), protone pomp inhibitors, glucocorticosteroids (GCs), laxatives, antiemetics (50%), nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines (20 - > 60%), paracetamol (a few to c. 50%), cardiovascular agents and diuretics (30-40%). Neuroleptics (mainly haloperidol) or low molecular weight heparin (LMWH) are administered to 10-20% of patients. In about 20% an antibiotic need to be introduced periodically. Some of them such as ciprofloxacin and clarithromycin are CYP3A4 inhibitors, similarly to antifungal azoles, including fluconazole (used up to > 10%). Multiple of the drugs, particularly opioids, anxiolytics, hypnotics, NSAIDs, GCs and LMWH may cause serious side effects and dangerous drug-drug interactions. The article presents the review of updated literature, with therapeutic implications, that may help physicians to order the most effective and safe management.
引用
收藏
页码:79 / 87
页数:9
相关论文
共 24 条
[1]   Is Oxycodone Efficacy Reflected in Serum Concentrations? A Multicenter, Cross-Sectional Study in 456 Adult Cancer Patients [J].
Andreassen, Trine Naalsund ;
Klepstad, Pal ;
Davies, Andrew ;
Bjordal, Kristin ;
Lundstrom, Staffan ;
Kaasa, Stein ;
Dale, Ola .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2012, 43 (04) :694-705
[2]   The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin [J].
Backman, JT ;
Kivistö, KT ;
Olkkola, KT ;
Neuvonen, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) :53-58
[3]   Drug interactions in palliative care [J].
Bernard, SA ;
Bruera, E .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) :1780-1799
[4]   The serotonin syndrome [J].
Boyer, EW ;
Shannon, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1112-1120
[5]   The Clinical Implications of Cytochrome P450 Interactions With Opioids and Strategies for Pain Management [J].
Brennan, Michael J. .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2012, 44 (06) :S15-S22
[6]   Prescribing in palliative care as death approaches [J].
Currow, David C. ;
Stevenson, James P. ;
Abernethy, Amy P. ;
Plummer, John ;
Shelby-James, Tania M. .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (04) :590-595
[7]   The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity [J].
Dunkley, EJC ;
Isbister, GK ;
Sibbritt, D ;
Dawson, AH ;
Whyte, IM .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2003, 96 (09) :635-642
[8]   Use of unnecessary medications by patients with advanced cancer: cross-sectional survey [J].
Fede, Angelo ;
Miranda, Michele ;
Antonangelo, Daniella ;
Trevizan, Ligia ;
Schaffhausser, Henrique ;
Hamermesz, Bruno ;
Zimmermann, Camile ;
Del Giglio, Auro ;
Riechelmann, Rachel P. .
SUPPORTIVE CARE IN CANCER, 2011, 19 (09) :1313-1318
[9]  
Frechen S, 2012, DRUG SAFETY, V35, P745, DOI 10.2165/11631280-000000000-00000
[10]   Drug interactions in palliative care - it's more than cytochrome P450 [J].
Gaertner, Jan ;
Ruberg, Klaus ;
Schlesiger, Grit ;
Frechen, Sebastian ;
Voltz, Raymond .
PALLIATIVE MEDICINE, 2012, 26 (06) :813-825